BLENREP vs LYNOZYFIC

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 11, 2026·How we rate

Possible drug interaction. BLENREP and LYNOZYFIC are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	BLENREP	LYNOZYFIC
Rating	70/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	BELANTAMAB MAFODOTIN-BLMF	LINVOSELTAMAB-GCPT
Manufacturer	Glaxosmithkline	Rengeneron Pharmaceuticals, Inc.
Dosage forms	Injectable	Injectable
Drug class	—	—
Boxed warning	Boxed warning	None
Treats	Multiple Myeloma	Multiple Myeloma

blenrep lynozyfic

Rating

70/100

New

Pharmacy pays

—

Type

Active ingredient

BELANTAMAB MAFODOTIN-BLMF

LINVOSELTAMAB-GCPT

Manufacturer

Glaxosmithkline

Rengeneron Pharmaceuticals, Inc.

Dosage forms

Injectable

Drug class

—

Boxed warning

None

Treats

Multiple Myeloma

Frequently asked questions

What is the difference between Blenrep and Lynozyfic?

Blenrep contains Belantamab Mafodotin-Blmf, while Lynozyfic contains Linvoseltamab-Gcpt — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.